An Open-Label, Dose-Escalating Study Of The Pharmacokinetics, Safety And Tolerability Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years.

Trial Profile

An Open-Label, Dose-Escalating Study Of The Pharmacokinetics, Safety And Tolerability Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2014

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Aug 2014 New trial record
    • 04 Jan 2011
    • 16 Mar 2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top